Objectives: Electroconvulsive therapy (ECT) remains one ofthe most effective biological treatmentsfor major depression. However, there is little information on the clinical use ofECT, and most studies were conducted before the introduction ofnewer antidepressants and before improvements in ECTdelivery. This study examinedECT use in a university teaching hospital to determine predictors ofshort-term ECT outcome.
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E lectroconvulsive therapy (ECT) continues to be one of the most effective biological therapies for patients with mood disorders. Recent task force reports from the American Psychiatric Association (I) and the United Kingdom Royal College of Psychiatrists (2) confirm that ECT is widelypracticed in psychiatric hospitals. Despite the common use of ECT, however, there is comparatively little systematic information on how ECT is used in clinical settings, withmost of the ECT studies published before 1990. Two recentdevelopments affecting the clinical use of ECT put into question the validity of findings from older studies. First is the important research showing that efficacy of unilateral ECT depends on using stimulus intensity greater than the minimal threshold required to produce a generalized seizure (3) . Thus,some patients inpast studiesmay not have received optimalcourses of unilateral ECT, if they received stimuli at just aboveseizure threshold. Second,a common indication for ECT is lackofresponse to antidepressant medications, since past studies showed that ECT is effective in patients who are resistant to March 1999 Short-Term Outcome in ECT 159 antidepressants. However, the antidepressants in those studies were limited to the older tricyclic antidepressants (TCAs) and monoamine oxidase inhibitor (MAOI) antidepressants. Numerous newer antidepressant medications are now available, including selective serotonin reuptake inhibitors (SSRIs), serotonin noradrenaline reuptake inhibitors (SNRIs), reversible inhibitors of MAO-A (RIMAs), and novel agents such as bupropion. Therefore, the type of patients now treated with ECT may be different from that in previous studies. For example, some patients referred for ECT may be more refractory to treatment because they had failed trials ofvarious antidepressants with different mechanisms of action. Alternatively, other patients may be referred for ECT without the benefit of a trial of what is still considered "gold standard" treatment with TCAs or MAOIs. To our knowledge, only 1 published study has examined the effect ofECT on patients who are resistant to the newer medications. In that study, resistance to SSRIs and MAOIs did not predict response to ECT, while resistance to TCAs was associated with a lower response rate (4) . This suggests that responses to different classes of medications may be an important factor in ECT response.
Given the limited clinical data on the recent use of ECT, we retrospectively examined the practice of ECT in our teaching hospital. We were specifically interested in who received ECT, the short-term results ofECT, the magnitude of memory disturbances with ECT, and whether any episode, treatment, or patient characteristics would predict short-term ECT response.
Methods

Setting
The psychiatric facilities at the University of British Columbia (UBC) Hospital comprise a 60-bed inpatient unit within a general medical centre on a university campus. The inpatient unit serves a defmed catchment area. Because Vancouver has a sectorized community mental health system, patients requiring psychiatric admission are generally admitted to the designated hospital in the sector oftheir residence, regardless ofwhere they are receiving treatment. At the time ofthe study, the hospital had 35 general community beds, ofwhich 10 were classified as short-stay (mean length of stay, 7.5 days), a 10bed Neuropsychiatry Unit, and a 15-bed Mood Disorders Unit. The Mood Disorders Unit is a tertiary care unit that accepts referrals from the province, but during the time ofthis study, the patient case mix was 70% secondary referrals (for example, admissions from the emergency room or transfers from the short-stay unit) and only 30% tertiary referrals.
ECT is conducted by a single specialist in a suite within the Mood Disorders Unit. Anesthesia is induced by sodium thiopental (2-3 mg/kg), and muscle relaxation is achieved by succinylcholine administration (0.5 mg/kg), Seizure threshold is quantified at the first treatment by the empirical titration procedure (3), and subsequent treatments are administered with an intensity 1.5-2 times the threshold for a course ofbilateral ECT and 3-5 times the threshold for a course of unilateral ECT. Atropine (0.6 mg intravenously) is given routinely only prior to the first treatment to prevent the bradycardia associated with the administration of subconvulsive stimuli (5, 6) . The machine used to administer ECT is the Thymatron apparatus with Flexdial Controller (Somatics Inc, Lake Bluff, Illinois). Frequency is set at 70 Hz and pulse width at 0.5 or 1.0 msec; current is set at 0.9 A by the manufacturer. The duration ofthe stimulus is the only variable used to determine the seizure threshold and delivery ofthe treatment. Seizure duration is monitored by the pressure cuffmethod (7) and a 2-lead (left frontomastoid) single channel electroencephalograph (EEG). Additional physiological monitoring includes electrocardiography, automated blood pressure monitoring, and pulse oximetry. Bilateral frontotemporal electrode placement is used for bilateral ECT, and the d'Elia electrode placement is used for unilateral ECT.
The choice ofelectrode placement for ECT is at the discretion of the referring psychiatrist. Most, but not all, referring psychiatrists prefer unilateral ECT as the initial treatment approach, since it is associated with fewer and less severe cognitive side effects. Patients are usually switched to bilateral ECT as early as after 4 unilateral ECT ifthere is no improvement or later in the course ifthere is no further progress over 2 or 3 consecutive treatments. A minority ofreferring psychiatrists routinely prescribe bilateral ECT, and all would choose bilateral over unilateral ECT when the risks ofprolonging the course of treatment (suicide, deteriorating physical condition, complicating medical conditions) outweigh the benefits of reduced cognitive side effects. Finally, bilateral ECT is usually prescribed first ifthere was a previous good response to bilateral ECT or ifa patient had failed a previous course of unilateral ECT.
Outcome Measures
This was a retrospective chart-review study and was thus dependent on the quality ofinformation recorded on the chart. As a teaching hospital, most inpatients are followed by either a resident or clerk-level medical student, so chart notes are usually detailed and complete. Demographics, diagnoses, symptoms, and course of illness were gathered from the patients' charts. A form was developed to record the chart information during the chart review (available on request). The number of adequate antidepressant trials for the current episode was determined from the chart notes. An antidepressant trial was rated adequate if patients took the minimum therapeutic dose or more for 4 weeks or longer. The degree ofcertainty or rigour of the trial was also noted, with rankings of definite (documented trial that was more than adequate, for example, using higher than minimum therapeutic doses for longer than 4 weeks), probable (documented trial previously noted adequate), or questionable (inconsistent notes, lack of detail of dose or duration). Only those antidepressant trials rated as defmite or probable were included as adequate trials. The severity ofthe depressive episode prior to receiving ECT 160 The CanadianJournal of Psychiatry Vol44,No2 admission was rated as mild, moderate, or severe based on the Clinical Global Impression (CGI) severity scale (8) .
ECT outcome was also rated based on the chart notes at 1 week after the last treatment or at discharge if that occurred sooner. The CGI scale ratings ofminimal or no improvement, much improved, or very much improved were compared with baseline. To be considered "much improved," the chart notes had to include indication of both subjective and objective improvement such that patients had an unequivocal response, although some mild residual symptoms may have been still present. To be rated "very much improved," the notes had to indicate that patients were almost back to baseline function with minimal residual symptoms. Cognitive side effects associated with ECT were also rated using a 3-point Likert scale with rankings of none or minimal, moderate, and marked. To be rated as moderate, the chart had to include subjective memory complaints with some distress or mildly impaired psychosocial function. To be rated as marked, there had to be additional objective behavioural indicators of significant memory disturbance (for example, forgetting their address or telephone numbers, needing to be accompanied on passes) or clinically significant impairment on bedside cognitive testing. The charts were reviewed, after appropriate training, by one person, and reliability was checked by having 15 random charts reviewed by another rater. A K rating of 0.6 to 0.8 is considered good interrater reliability for behavioural measures. The K ratings between the 2 raters were 0.66 for CGI severity, 0.75 for CG I improvement, and 0.73 for cognitive side effects, indicating good agreement. Nonparametric data (for example, CGI improvement, side effec~s severity) were analyzed using Mann Whitney U tests for 2 mdependent groups and Kruskal Wallis l-way ANOVA for more than 2 groups. Parametric data (for example, number ofECT treatments) were analyzed using ANOVA, followed by post hoc Student Newman Keuls tests to control for multiple comparisons. A stepwise multiple-regression analysis was also conducted, using parameters of P < 0.05 for variables to enter the regression equation, and P < 0.1 0 to exit. All statistical analyses were conducted using the Statistical Package for the Social Sciences (SPSS) for Windows (9) .
Results
Demographic Data
Betw~en April 1, 1994, and March 30, 1996, a total of 1555 patients were discharged from the psychiatric units at UBC Hospital, and 174 of these patients received ECT. The patients' diagnoses were unipolar major depressive disorder (MDD) (n = 130, 74.7%); bipolar disorder, depressed (bipolar typ~I, n = 19, 10.9%; bipolar type II, n = 7, 4.0%); and othe~diagnoses,~or example, Parkinson's disease (n = 18, 10.3 Y~). The~emamder of the results will focus on the group of patients WIth MDD (n = 130). All results are reported as group means ± SD.
De~ographic and episodic information for the MDD group mcluded an average age of51 ± 18 years (range, 19-91 years), 63% female, 37% male. The duration of the current depressive episode was 12.4 ± 15.2 months (range 1-72 months). Ninety pa~ients (64%) had recurrent depressive episodes, and the remamder were treated for a first episode ofdepression. The mean number of previous episodes of depression was 2.1 ± 1.8. Other comorbid diagnoses included dysthymia (n = 10, 8%), anxiety disorder (n = 8, 6%), and personality disorder (n = 18, 14%). Suicidal ideation occurred in 78% of the patients, with 24% of the total patients reporting previous suicide attempts. Psychosis (presence of hallucinations or delusions) was noted in 28 patients (22%). Of the vegetative symptoms, 86% reported insomnia, 7% hypersomnia, and 7% no change in sleep pattern. For appetite, 78% reported reduced appetite, 7% increased appetite, and 14% had no change. Similarly, for weight changes, 73% reported weight loss, 5% weight gain, and 22% no change. For severity ofthe current episode, 68% were rated as severely depressed while 32% were considered moderately depressed. '
The ECT indications for the MDD group included medication resistance, n = 96 (73.8%); need for rapid response, n = 80 (46.0%); and inability to tolerate medications because of side effects, n = 22 (12.6%). The numbers total more than 100% because some patients had more than 1 indication. Eighty patients (46%) previously had ECT, and 50 patients (38%) had a good response to ECT in the past.
Overall Outcome and ECT Parameters
n the chart review of CGI ratings at 1 week post-ECr, 17 patients (13%) were rated as minimally or not improved, 31 patients (2~%) as much improved, and 82 patients (63%)as very mUCh. Impro~ed (Table 1) . The ECT side effects during the same time penod were rated as minimal or none for 100 patients (77%), moderate for 21 patients (16%) and marked for 9 patients (7%). '
Of the 130 patients, 58 (45%) received unilateral BeT only, 46 (35%) received bilateral ECTonly, and 26 (20%)received both unilateral and bilateral ECT. For all patients, the number ofECT treatments ranged from 1 to 22, withamean number of8.9 ± 3.5, a median of8, and a mode of8 (Figure 1 ). e total num~er of ECTs received was higher in those patients who received both unilateral and bilateral ECr (unilat-e~al only: 8.2 ± 3.2; bilateral only: 8.5 ± 3.4; unilateral and bilateral: 11.4 ± 3.4; F(2, 127) = 9.0, P < 0.0005). However, there was no significant difference in the number of treatments between ECT responders (those rated as much improved or very much improved) and nonresponders (8.8±3.2 versus 10.0 ± 5.4, respectively; F(l, 128) = 1.6, P> 0.20).The s:verity ofcognitive side effects ofECT was not significantly different between patients who received unilateral ECr (none or minimal side effects: 83%; moderate: 14%; marked: 3%), bilateral ECT (none or minimal: 77%; moderate: 18%; marked: 5%), or both unilateral and bilateral ECT (none or minimal: 69%; moderate: 19%; marked: 12%) (Kruskal Wallis X 2 = 2.20, df= 2, P> 0.33).
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Short-Term Outcome in ECT 161 Table 1 . Clinical Global Impression ratings at 1 week post-ECT for patients with major depressive disorder (n = 130)8
"No significant differences were found for any of the comparisons (see text). edication failure defined as greater than minimal therapeutic dose of an antidepressant for at least 4 weeks. "Medication-resistant defined as 2 or more failed adequate antidepressant trials. ECT = electroconvulsive therapy; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant.
Figure 1. Number of ECT treatments received by patients with MOD (n=130)
Since SSRIs and TCAs were most commonly tried, we classified patients as having adequate trials of SSRIs only (n = 31, 24%), TCAs only (n = 24, 18%), both SSRIs and TCAs (n = 16, 12%), and neither SSRIs nor TCAs (n = 59, 45%). There were no significant differences in ECT outcome between these groups (Kruskal Wallis X 2 = 3.0, df= 3, P> 0.35). 
Medications Taken During ECT
Patients were on various medications during a course ofECT, including antidepressants (n = 66, 51%), antipsychotics (n = 50, 38%), benzodiazepines (n = 112, 86%), and anticonvulsants (n = 13, 10%). No patients were on lithium concurrently with ECT. There were no significant differences in CGI outcome between patients who were on or off medication in each medication class (Mann Whitney U tests, P > 0.40 for every comparison). Additionally, there were no differences on cognitive side effects of ECT, whether or not patients were concurrently taking the medications (Mann Whitney U tests, P> 0.17 for every comparison).
Other Predictors ofECT Outcome
There was no significant difference in ECT outcome between psychotic and nonpsychotic patients (Mann Whitney U = 1287, P > 0.44) or between patients rated as moderately or severely depressed (Mann Whitney U = 1744, P> 0.90).
A stepwise multiple-regression analysis ofECT outcome was conducted with entered variables including age, sex, duration of episode, number of previous episodes, presence of psychosis, antidepressant resistance, number of antidepressant trials, suicidal ideation, and the SSRI-or TCA-use grouping. No variables were identified that were predictive of short-term ECT outcome. 27 
Medication Trials Before ECT: Effects on Outcome Discussion
Prior to receiving ECT, 92% of patients had an adequate trial of at least 1 antidepressant. The medications used included SSRIs (n = 47,36%), TCAs (n = 40,31 %), moclobemide (n = 26,20%), venlafaxine (n = 11,8.5%), MAOIs (n = 11,8.5%), and bupropion (n = 7,5%). Augmentation strate-: gies that had failed included lithium (n = 28, 16%) and triio-. dothyronine (n = 12, 9%). The mean number of adequate : trials of medications received prior to ECT was 2.4 ± 1.6 . (range, 0-7). There were 81 patients (62%) classified as "treatment-resistant," defined as having a poor response to 2 : or more adequate antidepressant trials. There were no differ-I] ences in ECT outcome between these treatment-resistant pavtients and the others (Mann Whitney U = 1728, P> 0.30).
This chart-review study examined the clinical use ofECT and predictors of ECT outcome in a university teaching hospital. The strengths of this study are that it reports on a large number of patients, that a single clinician administered the ECT according to a current best-practices protocol, and that, given the sectorized system ofhospital care in Vancouver, the study sample is likely representative of community ECT use . The limitations of this study, however, must also be noted. Because it is a chart review, the information is entirely dependent upon the quality ofthe chart notes. This limitation is mitigated in part because the notes were usually detailed, particularly those recorded by medical students and residents. Since the outcome assessment was based entirely on clinician 162 The Canadian journal of Psychiatry Vol44,No2 notes, it may not accurately reflect subjective~provement, and/or the clinicians may be biased to report Improvement. Although formal prospective rating scales of outc~me were not used, the interrater reliability of the retrospective chartreview assessment was good, as indicated by the K statistics. Additionally, although Diagnostic and Statistical M.anual of Mental Disorders (DSM-IV) criteria were used, diagnoses were made using clinical assessments, structured diagnostic interviews were not obtained, and naturalistic treatment assignmentwas used. Therefore,these data may be lessreliable and valid than those obtained in prospective, randomized clinicaltrials. However,our sampleis likelymore representative of the "real world" clinicalpopulationbecause of the potential for selection bias in randomized studies (for example, volunteer bias, severity bias, strict inclusion and exclusion criteria).
Giventhese limitations,we describethe clinicalcharacteristics of a large sample of patients who received ECT over a 2-year period. There is, in fact, very limited information availableon patients who receive ECT. Most published studies reflect only clinical trial samples, and some were placebo-controlledstudies. Several surveysofECT use were published before the era of the newer antidepressantmedications and recent advances in ECT technique (10) (11) (12) . Other surveys involved smaller patient samples treated over a longertime period (13) . Despitesome ofthese differencesbetween studies, the clinical characteristics of patients receiving ECT in this survey are similar to those previously reported. At our centre, ECT was given to patients who were primarily depressed and who had been depressed for over a year before ECT. The proportion of patients with psychotic depression (22%) was lower than that reported in other surveys.The most common indicationfor ECTwas resistanceto antidepressantmedications(74%). In what may be an indication of the popularity of the newer medications, a substantial proportionof patients (65%) who had never had an adequate trial of a TCA or MAOI receivedECT. Eventhoughthe mean number of failed medication trials was 2.4, only 12% of the patientshad had both SSRI and TCAtrials. This suggeststhat TCAs may be underused as second-or third-line antidepressants in refractory depressed patients.
The mean number of ECTs received by patients was 8.9, and there were no significantdifferencesbetweenthose who received unilateral-only and bilateral-only ECT. The usual practice in our hospital is for patients to receive unilateral ECT first, unless they previously had a poor response to uni-lateralECT or respondedto bilateral ECT in the past. Nonresponders to unilateral ECT are usually switched to bilateral ECT. Therefore,it is not surprisingthat patientswho received both unilateral and bilateral ECT had a greater mean number of treatments.
As for outcome, we found that ECT had very good shortterm outcome, with 87% of patients rated as much improved or very much improved from baseline. ECT was also welltolerated, with 77% of patients described as having no or minimal cognitive side effects at 1 week following the last treatment and only 7% having marked side effects.
Clinical lore espouses that psychosis (presence of'hallud, nations and/or delusions) and psychomotor retardation are predictors of favourable ECT outcome. In part, this is based on results from some double-blind, placebo-controlledstudies (14, 15) and open naturalistic studies (16) showing that psychosis is associated with good ECT response. Similarly, some studies show that psychomotor retardation alsopredicts good ECT outcome (15, 16) . In contrast, however, otherstudies have not demonstrated that psychosis (controlled study: 17; open studies: 13, 18) or psychomotor retardation (controlled study: 14) predicts ECT response. Additionally, patients with neither psychosis nor psychomotor retardation were found to have good responses to ECT (controlledstudy: 19) . Our retrospective study supports these latter results by showingthat psychosis did not predict short-termresponse to ECT. Unfortunately,we did not have a good measureforpsychomotorretardation and thus were unable to evaluateitspredictive value.
Recently,medication resistance has been suggested tobea predictorof poor response to ECT (20) . Only 1ECTstudy has examined the effects of medication resistance to the newer antidepressant medications. Prudic and others showed that resistance to TCAs was associated with a significantly lower response rate to ECT, but that resistance to SSRIsor MAOIs did not affect response (4) . In this study, we foundthatresistance to TCAs and SSRIs did not differentially affect response. Similarly, the total number of failed adequate medication trials did not predict short-term outcome with ECT. The discrepantresults between the 2 studiesmaybedue to differences in methodology, particularly patientselection and outcome assessment. However, even thoughthestudy by Prudic and others found that the ECT response ofTCAnonresponders was significantly lower than that of SSRl nonresponders, the absolute response rate was still greater than 50%. This is an important clinical point, since clinicians can continue to be optimistic with patients about the short-tenn outcome with ECT, even if they have not responded well to antidepressant medications.
We did not fmd that medication use during a course of ECT affected response, whether the medications were anticonvulsants (n = 13), benzodiazepines (n = 112),or antidepressants (n = 66). Some studies have suggested that benzodiazepine use is associated with shorter seizures (presumablyby raising the seizure threshold) and poorerEeTTe· sponse (21, 22) . We did not examine the total dose of benzodiazepines, although we recommend at our centre that benzodiazepine use be kept to a minimum during EeT trea~ ment. Given that we did not fmd any effect of benzod» azepines on clinical response, any benzodiazepine effects on seizurethresholdmay have been offset by our use ofindividualized ECT doses and suprathreshold stimulus intensity.
In summary, we confirmed that ECT is safe and effective for patients with unipolar MOD. No particular clinical or March 1999 Short-Term Outcome in ECf 163 treatment predictors of short-term ECToutcome were identified. Specifically, the presence ofpsychosis and resistance to medications (TCAs and/or SSRIs) were not related to clinical outcome. Given the response and tolerability of ECT, it should be routinely offered as a treatment option to patients who have failed or are intolerant of antidepressant medications and/or who require a rapid antidepressant response.
